ArticleVeterinary research2025
A single-dose mRNA vaccine encoding the classical swine fever virus E2-ECD induces durable protective immunity in rabbits.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Classical swine fever virus (CSFV) spreads in domestic and wild pig populations, causing significant economic losses in the swine industry. Despite the global implementation of live attenuated vaccines, CSFV remains a persistent threat, with sporadic outbreaks reported annually. A major limitation of the current vaccines is safety concerns and the inability to differentiate infected from vaccinated animals (DIVA). The development of DIVA-compliant vaccines is desirable for effectively controlling or eradicating classical swine fever (CSF). Here, we developed two lipid nanoparticle (LNP)-encapsulated mRNA vaccines encoding either the extracellular domain of the CSFV envelope protein E2 (E2-ECD) or its N-terminal 172-amino acid fragment (E2-ECD-N). Immunological assays in mice revealed high antigenicity and long-lasting protective antibody responses from a single dose of either the E2-ECD or E2-ECD-N mRNA vaccine. Notably, both the E2-ECD and E2-ECD-N mRNA vaccines induced robust T cell responses in mice. Furthermore, a single dose (100 μg) of the E2-ECD mRNA vaccine was sufficient to induce long-term (up to 4 months) protective immunity against CSFV infection in rabbits. Our findings highlight the potential of CSFV-E2-based mRNA vaccines as promising strategies for effective CSF prevention and control while enabling DIVA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.